Skip to main content

Panbela Therapeutics, Inc. (PBLA)

NASDAQ: PBLA · IEX Real-Time Price · USD
1.97 0.06 (3.14%)
Nov 26, 2021 1:00 PM EST - Market closed

Company Description

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer.

The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.

The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was founded in 2011 and is based in Waconia, Minnesota.

Panbela Therapeutics, Inc.
Panbela Therapeutics Logo
CountryUnited States
Founded2011
IndustryBiotechnology
SectorHealth Care
Employees5
CEOMichael Cullen

Contact Details

Address:
712 Vista Blvd # 305
Waconia, Minnesota 55387-4559
United States
Phone952 479 1196
Websitepanbela.com

Stock Details

Ticker SymbolPBLA
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001029125

Key Executives

NamePosition
Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D.Chief Executive Officer, President and Director
Susan HorvathVice President of Finance, Chief Financial Officer, Secretary and Treasurer
Dr. Thomas X. NeenanCo-Founder and Chief Scientific Officer
Tammy GroeneVice President of Operations
Dr. Suzanne GagnonChief Medical Officer and Director

Latest SEC Filings

DateTypeTitle
Nov 10, 20218-KCurrent report
Nov 10, 202110-QQuarterly report [Sections 13 or 15(d)]
Sep 15, 20214Statement of changes in beneficial ownership of securities
Sep 15, 20214Statement of changes in beneficial ownership of securities
Aug 11, 202110-QQuarterly report [Sections 13 or 15(d)]
Aug 11, 20218-KCurrent report
Jul 2, 20218-KCurrent report
Jun 30, 2021424B5Prospectus [Rule 424(b)(5)]
Jun 30, 2021FWPFiling under Securities Act Rules 163/433 of free writing prospectuses
Jun 29, 2021FWPFiling under Securities Act Rules 163/433 of free writing prospectuses
View All SEC Filings